Register now to save up to $900

November 20-22, 2019
Boston, MA, USA

neo-antigen.com

NeoAg Summit

Personalized Neoantigen-based Cancer Vaccines & Immunotherapies



Weaponizing Neoantigens to Create Truly Personalized Cancer Vaccines & Cellular Immunotherapies

Expert Speakers Include:

Jessica Flechtner
CSO
Genocea

Andrew Allen
CEO
Gritstone

Stephen Schoenberger
Center Head, Professor, Division of Developmental Immunology
La Jolla Institute for Allergy & Immunology

Richard Gaynor
President of R&D
Neon Therapeutics

Fred Ramsdell
VP of Research
Parker Institute for Cancer Immunotherapy

Laurence Cooper
CEO
Ziopharm Oncology

Welcome to the 4th Annual **NeoAg Summit**

Your comprehensive guide to targeting tumor-specific neoantigens and bringing to market personalized cancer vaccines and cellular therapies.

Neoantigen-targeted therapies are fast becoming the hottest area in personalized immunotherapies. With significant breakthroughs in technology, join us as we optimize the discovery and prediction of neoantigens, accelerating the industry to advance into clinic and effectively target tumor indications.

The **NeoAg Summit** is the only industry-dedicated meeting focused on the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.

Leave this summit equipped with the knowledge and connections to **advance neoantigen prediction**, **improve immunogenicity** and **scale manufacture** to **improve the commercial potential of personalized therapies**.

Hear what previous attendees have to say

"Great opportunity to learn how to develop and accelerate neoantigen related products not only from speakers but also participants and partners"

BrightPath Biotherapeutics

"The best meeting I have found that focuses on neoantigens specifically"

ACT Genomics

Your Checklist to Developing Truly Personalized Cancer Immunotherapies

1 Evaluate Neoantigen Prediction Approaches

Identify therapeutically relevant tumor targets with conventional approaches led by **Gritstone Oncology** & **Agenus**, as well as novel approaches from **NeoPhore** & **Genocea**

2 Maximize Immunogenicity

Learn combination strategies from **Valo Therapeutics**, **Immunetune** & **Nouscom** to stimulate a stronger T cell response

3 Comprehensive Clinical Landscape

Gain a clear understanding from the leaders in the clinic with updates shared and lessons learned from **Vaccibody** & **Curevac**

4 Target Shared Neoantigens

Enhance the commercial potential of personalized vaccines with an off-the-shelf approach targeting shared neoantigens with **Ziopharm Oncology** & **Gritstone Oncology**

5 Streamline Manufacture to Reduce Needle to Needle Time

Clarify regulatory framework and streamline personalized manufacturing to decrease time and cost of production with expertise shared from **Kite, a Gilead Company** & **Vaximm**

Your Expert Speakers

Markus Dangl
CSO
Achilles Therapeutics

John Castle
Head of Translational Medicine & Bioinformatics
Agenus

Sandra Craig
Director, Manufacturing & Logistics
Agenus

Geoffrey Lynn
CEO
Avidea Technologies

Ulrike Gnad-Vogt
CMO & Head of Clinical Development
Curevac

Ronald Plasterk
CEO
Frame Therapeutics

Lelia Delamarre
Senior Scientist, Cancer Immunology Research
Genentech

Jessica Flechtner
CSO
Genocea

Tom Davis
CMO
Genocea

Andrew Allen
CEO
Gritstone Oncology

James Sun
Senior Director & Head of Bioinformatics
Gritstone Oncology

Rongfu Wang
Professor & Director of Center for Inflammation & Epigenetics
Houston Methodist

Julia Kodysh
Computational Researcher
Icahn School of Medicine at Mount Sinai

Norbert Hilf
VP of Translational Development
Immatics

Jeroen van Bergen
Director of Research
Immunetune

Willem-Jan Krebber
COO
ISA Pharmaceuticals

Christopher Choi
Senior Director, Process Development
Kite, a Gilead Company

Stephen Schoenberger
Center Head, Professor, Division of Developmental Immunology
La Jolla Institute for Allergy & Immunology

Richard Gaynor
President of R&D
Neon Therapeutics

Matthew Baker
VP of Immunology
NeoPhore

Anna Morena D'Alise
Immunology Lead
Nouscom

Trevor Clancy
CSO & Co-founder
OncoImmunity

Fred Ramsdell
VP of Research
Parker Institute for Cancer Immunotherapy

Antonella Vitiello
President & CEO
PersImmune, Inc.

Sean Boyle
Senior Director, Bioinformatics Applications
Personalis Inc

Trishul Shah
Director of Business Development
PolyPeptide Group

Claudine Bruck
BioMotiv Project Leader
SapVax

Kaidre Bendjama
Project Leader, Personalized Cancer Vaccines & Clinical Biomarkers
Transgene

David Stojdl
SVP of Discovery Research
Turnstone Biologics

Agnete Fredriksen
CSO
Vaccibody

Mette Husbyn
CTO
Vaccibody

Michael Stein
CEO
Valo Therapeutics

Heinz Lubenau
COO
Vaximm

Laurence Cooper
CEO
Ziopharm Oncology

"This was my first Hanson Wade Summit and I really enjoyed it. I was quite impressed by the quality of speakers. The meeting being focused on a single topic it was small enough in size to allow for good networking opportunities. It also offered a good representation of the state of the industry"

Parker Institute for Cancer Immunotherapy

Agenda at a Glance

Focus Day- November 20

Workshop A- Shared Neoantigens	Manufacturing Bootcamp
Workshop B- Combination Therapy	

Summit Day 1- November 21

Industry Leader's Keynote Session

Speed Networking

Prediction & Discovery	Clinical & Translational
Assessing Conventional Neoantigen Prediction Methods	Evaluating the Advantages & Disadvantages of Delivery Platforms

Lunch & Networking

Standardizing Neoantigen Discovery Processes to Uncover Best Validation Methods	Delivery Platforms to Maximise Immunogenicity

Afternoon Break & Poster Session

Industry Leader's Keynote Session

Summit Day 2- November 22

Industry Leader's Keynote Session

Morning Refreshments & Networking

Prediction & Discovery	Clinical & Translational
Generating Reliable Targets for Cellular Immunotherapy	Interrogating the Best Manufacturing Platforms to Reduce Needle to Needle Time

Lunch & Networking

Generating Reliable Targets for Cellular Immunotherapy	Interrogating the Best Manufacturing Platforms to Reduce Needle to Needle Time

Afternoon Refreshments

Novel Neoantigen Discovery Processes	Clinical Development for Adoptive Cell Transfer

Close of Summit

Workshop Day Wednesday, November 20

Workshop A

9.00 – 12.00

Exploring Shared/Public Neoantigens to Increase the Commercial Success of Neoantigen-based Therapies

Patient specific neoantigen therapies pose significant practical and regulatory challenges. However, targeting shared neoantigens across patients can mean highly effective off-the-shelf cancer vaccines.

Join this workshop discussion to identify where the challenges lie in targeting shared neoantigens for off-the-shelf immunotherapy.

Attendees will learn and discuss:

- Identification of shared neoantigens – approaches and data to date
- How to use shared neoantigens therapeutically
- Early clinical data – what are we learning?

Workshop Leader

Andrew Allen
CEO
Gritstone Therapeutics

Andrew Allen is co-founder of Gritstone Oncology, and President, CEO and a member of the BoD since August 2015. Previously he co-founded and was CMO at Clovis Oncology (NASDAQ: CLVS), and prior to that was CMO at Pharmion (acquired by Celgene in 2008 for $2.9B). He trained in Medicine at Oxford University, obtained a PhD in Immunology at Imperial College, and worked for several years at McKinsey & Company. He serves on the BoD of Epizyme (NASDAQ:EPZM), Sierra Oncology (NASDAQ:SRRA) and Revitope (private). He served on the BoD of Cell Design Labs, Inc until acquisition by Gilead in Dec 2017.

Workshop B

13.00 – 16.00

Improving Clinical Efficacy through Immunotherapy Combinations

Combinations of neoantigen-specific vaccines or adoptive cell therapies are promising to overcome the immunosuppressive mechanisms of the tumor microenvironment and improve immune responses. Clinical trials will determine the most effective combinations for tumor types.

Attendees will learn and discuss:

- How to identify biomarkers of clinical response
- Efficacy of cancer vaccines with immune checkpoints in various indications
- Optimize clinical trial design to provide meaning information

Workshop Leader

Michael Stein
CEO
Valo Therapeutics

Dr. Michael Stein, CEO of Valo Therapeutics, is a business leader and strategic adviser with C-suite experience in healthcare. Immediately prior to his appointment, Michael was the founding CEO of OxStem Ltd, an award-winning biotechnology spin-out from the University of Oxford, which broke the UK record for a seed round fund-raise of over £16m in May 2016.

In addition, Michael has served as founding CEO for Doctor Care Anywhere, acquired by Synergix in 2015. In 2001, he co-founded the Map of Medicine Ltd (the Map) with University College London. As founding CEO (and later CMO), the Map was nationally licensed across NHS England (2005-15) and acquired by Hearst Business Media (HBM) in 2008, after which Michael transitioned to executive vice-president of healthcare innovation.

Neoantigen Manufacturing & Regulations Bootcamp
Wednesday, November 20

Bootcamp 9.00 - 16.00

Addressing Manufacturing and Regulatory Challenges to Decrease Time & Cost of Neoantigen Therapeutic Development

It is important to maximise process development to decrease time and cost, streamlining the process and automating logistics. Release assays require streamlining but also ensure purity of cancer vaccines and cell therapy. The strategies for controlling cross contamination could influence the risk vs cost of neoantigen therapies.

As the cell therapy and cancer vaccine space advances and clinical investigations continue to produce promising results, uncertainty about the regulatory frameworks and procedures in place needs to be addressed. Attend this workshop to gain an in-depth understanding of the regulatory landscape for manufacture.

Attendees will learn and discuss:

- Challenges in the development of neoantigen targeted adoptive cell therapies
- Overcoming viral vector manufacturing challenges
- Automation strategies for T cell manufacture
- Kite case study outlining regulatory considerations for an analytical test method
- Improvements in regulatory requirements to help lower the testing demands
- In-depth case studies, guiding you through regulatory strategy and decision making throughout the development process

Workshop Leaders

Willem-Jan Krebber
COO
ISA Pharmaceuticals

Willem-Jan Krebber has over 15 years of experience in the pharmaceutical and biotechnology industry in various roles covering process development, manufacturing and project management. In his current role as Chief Operating Officer he leads all innovation, product development and manufacturing activities within the company. Prior to ISA Pharmaceuticals, he worked at OctoPlus (now Dr. Reddy's R&D) as CMC Program Manager where he was responsible for managing OctoPlus own product and technology development programs on advanced drug formulations and delivery. Prior to OctoPlus he held various CMC and project management positions at Crucell (now part of Janssen Vaccines & Prevention and Johnson & Johnson) for the development and manufacturing of cell-based products. Willem-Jan Krebber holds a Master in Biology from Utrecht University and a Masters in Biotechnology from Delft University of Technology.

Christopher Choi
Senior Director,
Process Development
Kite, a Gilead Company

Dr. Christopher Choi is Senior Director of Process Development, and PD Site Head for Neoantigens at Kite, a Gilead Company. He leads the Vector, T cell and Analytical teams in the development of adoptive cell therapies targeting patient-specific tumor neoantigens. Chris brings 18 years of experience in cell and gene therapy GMP manufacturing, Quality and process development. Prior to joining Kite, Chris served as the inaugural Director of Roswell's GMP compliant cell manufacturing facility, and served on faculty in the Depts. of Immunotherapy and Laboratory Medicine. Chris received his PhD from the University of Southern California and MBA from the Massachusetts Institute of Technology

Conference Day One
Thursday, November 21

8.00 Chair's Opening Remarks

Fred Ramsdell
VP of Research
Parker Institute for Cancer Immunotherapy

8.15 TESLA Consortium: Update on Neoantigen Predictions

- Over two dozen distinct computational pipelines exist for neoantigen prediction
- These pipelines utilize over a dozen different parameters to select peptides for vaccines
- The identity of the key factors in the selection of validated peptides are not clear
- Using 4 different bioassays, including patient-derived cells, the consortium is characterizing the key factors in peptide prediction

Richard Gaynor
President of R&D
Neon Therapeutics

8.45 Neoantigen Therapeutics Comes of Age

- Discuss experience utilizing a personal neoantigen vaccine in combination with a checkpoint inhibitor and, in certain cases, chemotherapy, to treat patients with high mutational burden tumors in the metastatic setting
- Outline Neon's personalized T cell approach, investigating ex vivo immunization of multiple T cell populations that are generated to target each individual patient's unique set of neoantigens
- Strategies to identify neoantigens that are conserved in specific tumors across a broader spectrum of patients which can be adapted for treatment through either vaccine or T cell based therapies

Sean Boyle
Senior Director, Bioinformatics Applications
Personalis Inc

9.15 ImmunoID NeXT Platform: Improving Neoantigen Predication, TME Assessment & ctDNA Detection for Vaccine Development

- Explore innovative genomics methods for a more comprehensive assessment of neoantigens
- Improve neoantigen to MHC binding prediction and ranking
- Assess TMR/TCR and tumor escape mechanisms that may impact vaccine response

9.45 Morning Refreshments & Speed Networking

This session is fast paced aiming to provide brief introductions to as many participants at the Macrophage-Directed Therapies Summit as early on in the meeting as possible. The renowned speed networking session will be one of the most valuable hours you spend at this summit.

Prediction & Discovery

Assessing Conventional Neoantigen Prediction Methods

10.45 Neoantigen Prediction: Approach and Validation

- Neoantigen identification for cancer immunotherapy remains a significant challenge
- Tumor immunopeptidomics combined with deep learning provides a powerful approach for neoantigen prediction
- Gritstone's EDGETM prediction model identifies therapeutically relevant neoantigens

James Sun, Senior Director & Head of Bioinformatics, **Gritstone Oncology**

Clinical & Translational

Evaluating the Advantages and Disadvantages of Delivery Platforms

10.45 Making Sure Neoepitopes are Properly Presented to CD8 T Cells by using a Unique Targeted Vaccine Delivery

- Inducing a unique CD8-dominated T cell response by targeting antigens to APC
- Discuss the link between immune responses, the optimal choice of neopitopes and anti-tumour efficacy
- Share clinical updates on the phase I/IIa VB N-01 trial in multiple indications

Agnete Fredriksen, CSO, **Vaccibody**

11.15 Neoantigen-specific T cell Responses: Learnings from Preclinical Studies with the RNA-LPX Vaccine

- Evaluate rules defining immunogenic neoepitopes
- Define mechanistic drivers of efficacy following vaccination

Lelia Delamarre, Senior Scientist, Cancer Immunology Research, **Genentech**

11.15 Harnessing Oncolytic Viruses for Personalized Neoantigen Immunotherapy

- Describe our novel T cell vaccine approach using engineered replicating viruses targeting personalized neoantigens
- Review our design approach to tackle several bottlenecks of current vaccine technologies regarding magnitude, breadth and persistence of CD8 T cell responses against multiple neoantigen targets
- Additionally, our virus based boosting strategy is uniquely modular and flexible for rapid clinical deployment

David Stojdl, SVP of Discovery Research, **Turnstone Biologics**

11.45 Connecting Neoantigens to TCR Recognition

- Evaluate how not all aberrations are equal in the eye of the immune system, only some non-self-aberrations are processed and presented
- Discuss how some presented peptides are recognised and impart effective immune response
- Outline how TCRs have a defined specificity for recognition
- Only some non-self-aberrations are processed and presented
- Only some presented peptides are recognised and impart effective immune response
- TCRs have a defined specificity for recognition

John Castle, Head of Translational Medicine & Bioinformatics, **Agenus**

11.45 mRNA Vaccines – A New Modality to Target Cancer Neoantigens

- mRNA based vaccines- design, mode of action and delivery
- Outline preclinical and clinical development
- Review regulatory considerations

Ulrike Gnad-Vogt, CMO & Head of Clinical Development, **Curevac**

12.15

YUBIO 裕策生物

12.15 Session details to be confirmed

12.45 Lunchtime Refreshments & Networking

Standardizing Neoantigen Discovery Processes to Uncover Best Validation Methods

13.45 Sources of Variability in Neoantigen Prediction

- Status update on neoantigen trials at Mount Sinai
- Description of the genomics/neoantigen prediction pipeline used for those trials
- Qualitative and quantitative comparison of several neoantigen prediction tools

Julia Kodysh, Computational Researcher, **Icahn School of Medicine at Mount Sinai**

14.15 Neoantigen in Myelodysplastic Syndromes

- Discuss challenges when targeting tumors with low mutational burden
- Outline antigen validation strategies

Antonella Vitiello, President & CEO, **PersImmune, Inc.**

Delivery Platforms to Maximise Immunogenicity

13.45 A Pyroptosis-inducing DNA Vaccine Adjuvant Amplifies Tumour-specific T Cell Responses and Tumour Control

- Pyroptosis is a form of inflammatory cell death involving caspase-1 activation
- Outline our design for a constitutively active form of caspase-1
- DNA coding for active caspase-1 improves the immunogenicity of neoantigen DNA vaccines

Jeroen van Bergen, Director of Research, **Immunetune**

14.15 NousCom Neoantigen-based Cancer Vaccine for potent, broad and effective anti-tumor T cell immunity

- Define how neoantigen vaccines based on Adenoviruses derived from non-human Great Apes (GAd) elicit strong immune response and are highly effective as stand-alone treatment, however treatment of large tumors requires combination of GAd with checkpoint inhibitors (CPI)
- Review how the effectiveness of vaccination is CD8 mediated and correlates with the breadth and potency of T cell responses induced by vaccination, including the expansion of the intratumoral T cell repertoire

Anna Morena D'Alise, Immunology Lead, **Nouscom**

14.45 Antigens that Matter - Highly Personalized Immunotherapy Approaches Applying the XPRESIDENT® Technology

- Review immatics XPRESIDENT® target discovery technology in the context of personalization
- Discuss neoantigens and unmutated antigens – chances and challenges
- Outline the highly personalized Adoptive Cellular Therapy
- GAPVAC approach: concept of actively personalized vaccination in newly diagnosed glioblastoma

Norbert Hilf, VP of Translational Development, **Immatics**

14.45 Using Combination of Viral Vectors to Maximize Efficacy of Cancer Vaccines

- Outline the use of viruses to prime against neoantigen sequences
- Review the effect of viruses on the adaptive response against the tumor
- Discuss the combination of various viral modalities to address lead time issues and maximize potency

Kaidre Bendjama, Project Leader, Personalized Cancer Vaccines & Clinical Biomarkers, **Transgene**

15.15 Afternoon Break & Poster Session

Andrew Allen
CEO
Gritstone Oncology

16.15 Using Normal Immune Responses as the Engine for Cancer Immunotherapy

- Antigen selection - define the power of neoantigens
- Antigen delivery – setting immunologic goals and choosing the right vectors for humans
- Are we meeting the goal(s) and seeing clinical efficacy?

Trevor Clancy
CSO & Co-founder
OncoImmunity

16.45 An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

- Outline a high-performing machine learning approach, trained on mass spectrometry data, that predicts naturally processed and presented antigens
- Demonstrate how the predictor is integrated with several immune parameters, such HLA binding, in a deep learning layer to predict bona fide neoantigens
- Illustrate it's application to significantly improve the identification of neoantigen targets for personalized cancer immunotherapy

Tom Davis
CMO
Genocea

17.15 Shouldn't Each Patient's Immune System Define True Personalized Neoantigens?

- ATLAS™, an autologous immune assay that identifies specific immunogenic neoantigens, is more effective at identifying true neoantigens for both CD4 AND CD8 targets than algorithms predictions focused on MHC presentation, and also identifies immunosuppressive peptides
- GEN-009, a neoantigen vaccine, is feasible and safe for patients
- Share clinical data from resected cancer patients show broad and robust immune responses against the vast majority of vaccine antigens selected by ATLAS

17.45 Chair's Closing Remarks

17.45 NeoAg Summit Drinks Reception

"The Neoantigen Summit is the focal point for updates in the cancer neoantigen vaccine field and should be attended by everybody with a keen interest in the field"

Vaccibody

Conference Day Two
Friday, November 22

8.00 Chair's Opening Remarks

Michael Stein
CEO
Valo Therapeutics

Claudine Bruck
BioMotiv Project Leader
SapVax

8.15 Panel Discussion: The Clinical Potential and Challenges of Neoantigen-based Therapies with Immunotherapy Combinations

- Outline combination strategy and design for ICI or T cell therapies
- Discuss regulatory pathway and limitations to approve two new drugs
- How to identify a clear biologic effect caused by combination
- Review combination approach for different vaccine modalities

9.00 Optimization of Cancer Vaccine Development by using Multiplexed Identification of T-cell Receptor Antigen Specificity (MIRA)

- Generating immunogenicity data to antigens of interest at scale informs antigen selection for improved vaccine design and development
- Adaptive Biotechnologies has developed a novel, highly sensitive approach know as Multiplexed Identification of T cell Receptor Antigen specificity (MIRA)
- MIRA combines high-throughput T-cell receptor (TCR) repertoire sequencing with conventional immune techniques to assess T cell specificity to hundreds of query antigens at a time with a sensitivity of one in 10 million naïve human T cells
- To validate this approach, we assessed biologically relevant T-cell immune reponses against more than 35 neoepitopes using T cells sourced from the naïve repertoire of 50 healthy donors to leverage the massive diversity of the naïve TCR and identify ultra-low frequency antigen-specific T cell reponses.

Trishul Shah
Director of Business Development
PolyPeptide Group

9.30 A CMO's Approach to Supporting Personalized Peptide Vaccines

- Outline what PolyPeptide has set-up
- Share our approach to regulatory aspects of personalized peptide vaccines
- Review challenges and how they were overcome

10.00 Morning Refreshments & Networking

Prediction & Discovery

Generating Reliable Targets for Cellular Immunotherapy

11.00 Identifying Natural Ligands for Neoantigen Immunotherapy

- Discuss how effective personalized neoantigen vaccination will require targeting the subset of mutations that generate MHC-bound ligands recognized by CD4+ and CD8+ T cells
- Current predictive algorithms appear to only be useful for high tumor mutational burden and do not include mutations recognized by CD4+ T cells
- Describe the development of a novel MHC-agnostic platform that uses functional responses from a patient's own immune system to identify neoantigens for both T cell subsets

Stephen Schoenberger, Center Head, Professor, Division of Developmental Immunology, **La Jolla Institute for Allergy & Immunology**

Clinical & Translational

Interrogating the Best Manufacturing Platforms to Reduce Needle to Needle Time

11.00 Oral T-Cell Therapies for Personalized Neoantigen-Targeting Treatment

- Evaluate Vaximm's oral bacteria-based DNA vaccination platform
- Optimizing time to administration
- Patient-convenient personalized anti-cancer treatment

Heinz Lubenau, Chief Operating Officer, **Vaximm**

11.30 Beyond Algorithms: The ATLAS Bioassay Method for Neoantigen Identification and Characterization

- HLA agnostic assay identifies CD4 and CD8 T cell neoantigens
- Uniquely distinguishes mutations that elicit stimulatory and inhibitory T cell responses
- Personalized neoantigen vaccine using ATLAS entering clinical development

Jessica Flechtner, CSO, **Genocea**

11.30 Process Development to Production: Steps Taken, Decisions, Lessons Learned

- Experience establishing a compliant process to comply with regulatory guidelines
- Outline team efforts, communication and training
- Review execution and delivery of GMP product

Sandra Craig, Director, Manufacturing & Logistics, **Agenus**

12.00 Lunchtime Refreshments

13.30 Improving Prediction Accuracy with T Cell Assays

- Review how T cell assays can screen and identify immunodominant neoantigens in a more accurate way than conventional prediction methods
- Discuss how to improve neoantigen prediction based on antigen expression, processing and presentation, interaction and triggering of TCRs.
- Outline how to develop neoantigen-based personalized immunotherapy

Rongfu Wang, Professor & Director of Center for Inflammation & Epigenetics, **Houston Methodist**

13.30 Enabling Personalized Cancer Vaccines with Self-assembling Nanoparticles

- Discuss properties of peptide-based vaccines that impact efficiency of T cell priming in vivo
- Self-assembling nanoparticles enable rapid manufacturing and improve T cell induction
- Validation in mouse and primate models; boost strategies to maximize efficacy

Geoffrey Lynn, CEO, **Avidea Technologies**

14.00 Round Table Discussion: Improving Neoantigen Prediction

Join this session to discuss with your colleagues, the current challenges in identifying clinically relevant neoantigen targets and leave with your questions answered from the leaders in this field.

14.00 How to Overcome Regulatory Challenges in the Development of Personalized Cancer Vaccines

- Outline the manufacturing platform for a plasmid DNA vaccine
- Review the game changing regulatory environment
- Discuss the need to streamline logistics to improve the cost and process design for personalized therapies

Mette Husbyn, CTO, **Vaccibody**

14.30 Afternoon Refreshments

Novel Neoantigen Discovery Processes

15.00 Frame Shift Neoantigens as Targets for Personalized Yet Off-the-shelf Anti-cancer Vaccines

- The majority of newly encoded amino acid sequences in human cancers are the result of frameshift mutations
- Many frameshift neoantigens ('Frames') are shared among different cancer patients. Therefore Frames are good targets for off-the-shelf vaccination

Ronald Plasterk, CEO, **Frame Therapeutics**

15.30 Mismatch Repair Drugs for Cancer Immunotherapy

- Inhibition of DNA mismatch repair (MMR) generates new immunogenic neoantigens in tumors
- NeoPhore is developing a new class of MMR inhibitors to increase tumor mutation burden
- Inhibition of the MMR pathway leads to MSI high tumors that have been shown to be more susceptible to treatment with first-line immunotherapy

Matthew Baker, VP of Immunology, **NeoPhore**

Clinical Development for Adoptive Cell Transfer

15.00 Exploiting the Principles of Tumour Evolution to Develop Personalised T Cell Therapies to Treat Solid Cancers

- Tumour evolution and intratumoural heterogeneity
- Identification of clonal neoantigens
- Manufacturing of clonal neoantigen reactive T cells (cNeT) for clinical studies

Markus Dangl, CSO, **Achilles Therapeutics**

15.30 Targeting of Shared and Unique Neoantigens by Genetically Modified T Cells for the Treatment of Solid Tumors

- One or more neoantigens within and outside hotspots that are expressed by tumors are targets for T-cell therapy
- Outline how T cells can be genetically modified using the Sleeping Beauty (SB) system to express neoantigen-specific T-cell receptors (TCRs) enabling the personalization of T-cell therapy
- SB-modified TCR-T can be produced at scale needed to target neoantigens to address the numbers of patients (inter-tumor heterogeneity of neoantigens) and prevent relapse (intra-tumor heterogeneity of neoantigens)

Laurence Cooper, CEO, **Ziopharm Oncology**

16.00 Chair's Closing Remarks & End of Summit

Sponsor

Industry Development Partner

OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.

www.oncoimmunity.com

Expertise Partner

Adaptive Biotechnologies is a pioneer in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive Therapeutics' platform allows the discovery of potent, ultra-low frequency TCRs with differentiated therapeutic potential. This TruTCRTM engine combines Adaptive's foundational immunosequencing platform with a multiplex approach to map TCRs to antigens at high specificity plus pairSEQTM to accurately pair TCR alpha/beta chains. Adaptive has discovered and is validating candidate TCRs with superior cytolytic activity in oncology.

www.adaptivebiotech.com

Expertise Partner

Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other nextgeneration cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies.

www.personalis.com

Expertise Partner

The PolyPeptide Group employs approximately 750 staff at sites in Belgium, France, India, Sweden and the USA. The PolyPeptide Group is the world's largest independent contract manufacturer of therapeutic peptides. The privately-held organization manufactures over one third of all approved peptide drug substances and accounts for over 30% of the sales of outsourced peptide therapeutics worldwide. The Group offers its customers an almost unprecedented long-term security of supply with six GMP facilities worldwide and an exclusive focus on pharmaceutical peptide manufacture.

www.polypeptide.com

Partners

Industry Partner

IOVAXIS THERAPEUTICS
Fighting Cancer with Your Own Weapons

Programme Partner

YUBIO 裕策生物

Hosting Partner

CEM

Exhibitors

ALMAC BACHEM CAPRION Cayman CHEMICAL CPC scientific MEDGENOME TrakCel

There is no one size fits all approach to partnerships at our events. Your business has specific goals this year. When you work with us we will build a partnership that helps you achieve those aims.

Partner with Us

Jennifer MacKay & **Luke O'Neil**
Partnerships Director
Tel: +16174554188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways To Book

www.neo-antigen.com/register

Tel: +1 212 537 5898

Email: register@hansonwade.com

Team Discounts*

- **10% discount –** 3 delegates
- **15% discount –** 4 delegates
- **20% discount –** 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Industry Pricing*	Register & Pay By Friday 19 July	Final Registration Prices
Conference + Bootcamp	$3,197 **(save $900)**	$3,997 **(save $200)**
Conference + 2 Workshops **(A & B)**	$3,197 **(save $900)**	$3,997 **(save $200)**
Conference + 1 Workshop **(A or B)**	$2,598 **(save $800)**	$3,398 **(save $100)**
Conference Only	$2,099 **(save $700)**	$2,799

Solution Provider Pricing	Register & Pay By Friday 19 July	Final Registration Prices
Conference + Bootcamp	$3,697 **(save $900)**	$4,397 **(save $200)**
Conference + 2 Workshops **(A & B)**	$3,697 **(save $900)**	$4,397 **(save $200)**
Conference + 1 Workshop **(A or B)**	$3,098 **(save $800)**	$3,798 **(save $100)**
Conference Only	$2,499 **(save $700)**	$3,199

*Industry Pricing is reserved for pharmaceutical and biotech companies actively and publically developing neoantigen based therapeutics, that do not offer pay-for services.
Academic pricing available, please email register@hansonwade.com for more information.

Venue

The Colonnade
120 Huntington Avenue, Boston
MA 02116, USA

For further information or assistance, please visit www.colonnadehotel.com

Code: 000